Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Treatment of HIV-associated Neurocognitive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* Maintained on stable ART for ≥6 months (defined as undetectable viral load)~* HAND-MND or -ANI diagnosis with evidence of clinical onset or progression within the prior 2 years, based on established criteria~* Currently followed at the Southern Alberta Clinic (SAC; Calgary, AB, Canada)~Exclusion Criteria:~* HAND with a) changed dose of any medication for HIV-1 infection with a corresponding increase in viral load (e.g., ART), or b) secondary therapies for HAND (e.g., memantine, amphetamines).~* Advanced liver, renal or lung disease, cancer or diabetes requiring insulin~* Secondary diagnosis of neurocognitive impairment or other major neuropsychiatric illness such as epilepsy, Alzheimer's or Parkinson's diseases, major depression (PHQ-9 score \>10), or schizophrenia~* Central nervous system lesion (diagnosed by neuroimaging) that may impair cognition~* Previous allergic reaction to insulin or any of the carrier components.~* Education \< 9 years or inability to read and write English fluently~* Uncontrolled HIV-1 or hepatitis C co-infection~* Inability to perform NP or questionnaire measures, functional illiteracy~* Past or current substance abuse that could interfere with the study assessments as determined by the PI~* Marijuana use on the day of NP testing~* Uncontrolled cardiovascular disease (hypertension, coronary or peripheral artery disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IN insulin 40 IU (Type: ACTIVE_COMPARATOR): Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
- IN Sterile Saline (Type: PLACEBO_COMPARATOR): Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).